Clinical trial
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
NCT03513952 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 5, 2019
- Completion date
- April 1, 2024
- Enrollment
- 47 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
advanced bladder urothelial carcinoma, advanced ureter urothelial carcinoma, metastatic bladder urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, metastatic urothelial carcinoma, recurrent bladder urothelial carcinoma, recurrent renal pelvis urothelial carcinoma, recurrent ureter urothelial carcinoma, recurrent urethral urothelial carcinoma, stage iii bladder cancer ajcc v8, stage iii renal pelvis cancer ajcc v8, stage iii ureter cancer ajcc v8, stage iii urethral cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv renal pelvis cancer ajcc v8, stage iv ureter cancer ajcc v8, stage iv urethral cancer ajcc v8, stage iva bladder cancer ajcc v8, stage ivb bladder cancer ajcc v8, unresectable bladder urothelial carcinoma, unresectable renal pelvis urothelial carcinoma, unresectable ureter urothelial carcinoma